Your browser doesn't support javascript.
loading
An Adrenal Incidentaloma Diagnosed as Dopamine-Secreting Pheochromocytoma: A Case Report.
Jing, Jing; Yu, Minmin; Jiang, Bo.
Afiliação
  • Jing J; Department of Endocrinology, Qingdao Municipal Hospital, Qingdao, Shandong 266071, China.
  • Yu M; Department of Endocrinology, Qingdao Municipal Hospital, Qingdao, Shandong 266071, China.
  • Jiang B; Department of Urology, Qingdao Municipal Hospital, Qingdao, Shandong 266071, China. Electronic address: jiangboqdy@126.com.
J Natl Med Assoc ; 113(1): 46-50, 2021 Feb.
Article em En | MEDLINE | ID: mdl-32741578
ABSTRACT

BACKGROUND:

Dopamine-secreting pheochromocytomas are exceedingly rare. CASE PRESENTATION A 28-year-old woman, who was admitted due to 4 hours of acute-onset abdominal pain, detected an adrenal mass incidentally. She was almost asymptomatic without a known family history. Laboratory assessments showed significant increases in dopamine levels of serum and 24-h urinary. By using preoperative a-adrenergic receptor blockers, she developed orthostatic hypotension and palpitations. When she underwent laparoscopic left adrenalectomy, she experienced rapid cyclic fluctuations in systolic blood pressure from 90 mmHg to 200 mmHg. Postoperatively, she exhibited prolonged hypotension, requiring vasopressor therapy and fluid replacement. According to histopathological diagnosis, it was a pheochromocytoma. Dopamine levels in 24-h urine and serum decreased to normal after operation. Analysis of specific gene SDHB, SDHD, RET, VHL and NF1 detected no pathogenic mutations.

CONCLUSION:

Patients with dopamine-secreting pheochromocytomas are mostly asymptomatic, leading to a significant delay in diagnosis. There is a large possibility for dopamine-secreting pheochromocytomas to show a malignant tendency than the adrenergic and noradrenergic phenotypes. The a-adrenergic receptor blocker is not indicated for preoperative medical treatment because it can cause hypotension and cardiovascular failure. Calcium channel blockers or metyrosine may be better alternatives. All patients with pheochromocytomas should receive targeted genetic testing based on specific clinical features. SDHB, SDHD, RET, VHL and NF1 mutations are suggested for genetic testing of adrenal dopamine-secreting pheochromocytomas.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Feocromocitoma / Neoplasias das Glândulas Suprarrenais Tipo de estudo: Diagnostic_studies Limite: Adult / Female / Humans Idioma: En Revista: J Natl Med Assoc Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Feocromocitoma / Neoplasias das Glândulas Suprarrenais Tipo de estudo: Diagnostic_studies Limite: Adult / Female / Humans Idioma: En Revista: J Natl Med Assoc Ano de publicação: 2021 Tipo de documento: Article